



**Shanghai Bao Pharmaceuticals Co., Ltd.**  
**上海寶濟藥業股份有限公司**

(A joint stock company established in the People's Republic of China with limited liability)  
(於中華人民共和國成立的股份有限公司)  
(Stock Code 股份代號 : 2659)

16 January 2026

Dear registered shareholder(s),

**Arrangement of Electronic Dissemination of Corporate Communications**

Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, Shanghai Bao Pharmaceuticals Co., Ltd. (the “**Company**”) is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the “**Corporate Communications**”), which mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at [www.baopharma.com](http://www.baopharma.com) and the HKEXnews website at [www.hkexnews.hk](http://www.hkexnews.hk) in place of printed copies.

Solicitation of electronic contact details

To ensure timely receipt of the Actionable Corporate Communications<sup>(Note)</sup>, the Company recommends you provide your email address by scanning your personalized QR code printed on the enclosed reply form (the “**Reply Form**”). Alternatively, you may sign and return the Reply Form to the Company’s H share registrar (the “**H Share Registrar**”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong.

**If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the H Share Registrar, you (i) need to proactively check the Company’s website and the HKEXnews website to keep up with the publication of Corporate Communications; and (ii) the Company will send the Actionable Corporate Communications<sup>(Note)</sup> in printed form in the future.**

If you want to receive the future Corporate Communications in printed form, please complete and return the Reply Form to the H Share Registrar or send an email to [Baopharma.ecom@computershare.com.hk](mailto:Baopharma.ecom@computershare.com.hk) specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to this letter, please contact the H Share Registrar by sending an email to [Baopharma.ecom@computershare.com.hk](mailto:Baopharma.ecom@computershare.com.hk).

Yours faithfully,  
By order of the Board  
**Shanghai Bao Pharmaceuticals Co., Ltd.**  
**Dr. Liu Yanjun**  
Chairman of the Board and Executive Director

*Note: Actionable Corporate Communication is any corporate communication that seeks instructions from issuer’s securities holders on how they wish to exercise their rights or make an election as the issuer’s securities holder.*

各位登記股東：

**以電子方式發佈公司通訊之安排**

根據自 2023 年 12 月 31 日起生效的擴大無紙化上市機制及以電子方式發佈公司通訊規定下香港聯合交易所有限公司證券上市規則第 2.07A 條，上海寶濟藥業股份有限公司（「**本公司**」）謹此通知 閣下，本公司已採用以電子方式發佈公司通訊（「**公司通訊**」）之安排，該公司通訊是指本公司為向其任何證券持有人提供資訊或提醒其採取行動而發佈或將要發佈的任何文件，包括但不限於(a) 董事報告、年度帳目以及審計報告副本以及（如適用）財務摘要報告；(b) 中期報告及其中期報告摘要（如適用）；(c) 會議通知；(d) 上市文件；(e) 通函和 (f) 委任表格。

請注意，所有日後公司通訊的英文版和中文版將在本公司網站 [www.baopharma.com](http://www.baopharma.com) 和披露易網站 [www.hkexnews.hk](http://www.hkexnews.hk) 上提供，以代替印刷本。

徵集電子聯絡資料

為確保及時收到可供採取行動的公司通訊<sup>(附註)</sup>，本公司建議 閣下透過掃描本函隨附之回條（「**回條**」）上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。或者， 閣下也可以簽署回條並交回本公司的 H 股股份過戶登記處（「**H 股股份過戶登記處**」）香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

**如果本公司沒有收到 閣下的有效電子郵件地址，直至 H 股股份過戶登記處收到 閣下有效的電子郵件地址前， 閣下(i)需要主動查看本公司網站和披露易網站以留意公司通訊的發佈；及(ii)本公司未來將以印刷本形式發送可供採取行動的公司通訊<sup>(附註)</sup>。**

若 閣下希望收取日後公司通訊之印刷本，請填妥回條並交予 H 股股份過戶登記處，或發送電子郵件至 [Baopharma.ecom@computershare.com.hk](mailto:Baopharma.ecom@computershare.com.hk)，並註明 閣下的姓名、地址以及收取公司通訊印刷本的要求。請注意，收取日後公司通訊印刷本之指示由收悉 閣下指示當日起計一年內有效，此後將告失效。

如 閣下對本函件有任何疑問，請發送電子郵件至 [Baopharma.ecom@computershare.com.hk](mailto:Baopharma.ecom@computershare.com.hk) 向 H 股股份過戶登記處查詢。

承董事會命  
上海寶濟藥業股份有限公司  
董事長兼執行董事  
**劉彥君博士**  
謹啟

2026 年 1 月 16 日

附註：可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊。



當閣下寄回此回條時，請將郵寄標籤剪貼於信封上。  
如在本埠投寄，閣下無需支付郵費或貼上郵票。